secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2026-09-08T11:05:26+00:00
Accession:  0001372514-26-000079
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora appoints Keith Lane as EVP of Clinical Development and Regulatory Affairs
-------------------------------------------------------------------------------

- Lane appointed EVP, Head of Clinical Development and Regulatory Affairs effective Sept 8, 2026.
- Compensation: $350k base salary, $75k sign-on bonus, 35% base target bonus, 55k share option grant.
- Lane brings 20+ yrs ophthalmic experience from Ora; oversaw 60+ trials, incl. 12 global Phase 3 studies.
- Will lead U.S./global clinical development for KIO-301 (retinitis pigmentosa) and other pipeline assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000079/0001372514-26-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000079/kprx-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001372514-26-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer